Company intelligence / Profile preview

Pythia Science

Ownership: Private
Development stage: Other

Overview

Pythia Biotech has developed award-winning organ-on-chip platforms that simulate human physiological environments, enabling more accurate preclinical drug testing and supporting personalized medicine approaches. Their tumor microenvironment chip is used in lung cancer research, while their liver chip aids in hepatotoxicity studies. The company has received multiple innovation awards and established partnerships with major pharma companies like Merck to advance organ-on-a-chip technologies.

Therapeutic areas: OncologyGastroenterology
Modalities: Organ-on-chip technologyIn vitro drug testing platformsMicrofluidic bio-chips
Industry: Non-Drug Biotech

Partnerships

Merck (strategic partnership on organ-on-a-chip)Boehringer Ingelheim (“Grass Roots” Support Program)

Beyond the preview

Go deeper on Pythia Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pythia Science.

Explore the full profile